Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature.

Dermatology and therapy

Weidmann A, Foulkes AC, Kirkham N, Reynolds NJ.
PMID: 24942326
Dermatol Ther (Heidelb). 2014 Dec;4(2):145-56. doi: 10.1007/s13555-014-0056-z. Epub 2014 Jun 19.

Methotrexate continues to be one of the most widely used systemic immunosuppressive agents in dermatology. In addition to the important, well-characterized adverse effects such as hepatotoxicity and myelosuppression, methotrexate may induce a number of rare cutaneous adverse events including...

Cite
Weidmann A, Foulkes AC, Kirkham N, et al. Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature. Dermatol Ther (Heidelb). 2014;4(2):145-56doi: 10.1007/s13555-014-0056-z.
Weidmann, A., Foulkes, A. C., Kirkham, N., & Reynolds, N. J. (2014). Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature. Dermatology and therapy, 4(2), 145-56. https://doi.org/10.1007/s13555-014-0056-z
Weidmann, Anja, et al. "Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature." Dermatology and therapy vol. 4,2 (2014): 145-56. doi: https://doi.org/10.1007/s13555-014-0056-z
Weidmann A, Foulkes AC, Kirkham N, Reynolds NJ. Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature. Dermatol Ther (Heidelb). 2014 Dec;4(2):145-56. doi: 10.1007/s13555-014-0056-z. Epub 2014 Jun 19. PMID: 24942326; PMCID: PMC4257944.
Copy Download .nbib Format: NLM
Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells.

Stem cells translational medicine

Heslop JA, Kia R, Pridgeon CS, Sison-Young RL, Liloglou T, Elmasry M, Fenwick SW, Mills JS, Kitteringham NR, Goldring CE, Park BK.
PMID: 28749066
Stem Cells Transl Med. 2017 Aug;6(8):1751. doi: 10.1002/sctm.12187. Epub 2017 Jun 15.

No abstract available.

Cite
Heslop JA, Kia R, Pridgeon CS, et al. Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells. Stem Cells Transl Med. 2017;6(8):1751doi: 10.1002/sctm.12187.
Heslop, J. A., Kia, R., Pridgeon, C. S., Sison-Young, R. L., Liloglou, T., Elmasry, M., Fenwick, S. W., Mills, J. S., Kitteringham, N. R., Goldring, C. E., & Park, B. K. (2017). Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells. Stem cells translational medicine, 6(8), 1751. https://doi.org/10.1002/sctm.12187
Heslop, James A, et al. "Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells." Stem cells translational medicine vol. 6,8 (2017): 1751. doi: https://doi.org/10.1002/sctm.12187
Heslop JA, Kia R, Pridgeon CS, Sison-Young RL, Liloglou T, Elmasry M, Fenwick SW, Mills JS, Kitteringham NR, Goldring CE, Park BK. Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells. Stem Cells Transl Med. 2017 Aug;6(8):1751. doi: 10.1002/sctm.12187. Epub 2017 Jun 15. PMID: 28749066; PMCID: PMC5689756.
Copy Download .nbib Format: NLM
Solving the problem of dose optimization of children's medicines.

Expert review of clinical pharmacology

McWilliam SJ, Hawcutt DB.
PMID: 29355041
Expert Rev Clin Pharmacol. 2018 Mar;11(3):205-208. doi: 10.1080/17512433.2018.1431528. Epub 2018 Jan 30.

No abstract available.

Cite
McWilliam SJ, Hawcutt DB. Solving the problem of dose optimization of children's medicines. Expert Rev Clin Pharmacol. 2018;11(3):205-208doi: 10.1080/17512433.2018.1431528.
McWilliam, S. J., & Hawcutt, D. B. (2018). Solving the problem of dose optimization of children's medicines. Expert review of clinical pharmacology, 11(3), 205-208. https://doi.org/10.1080/17512433.2018.1431528
McWilliam, Stephen J, and Hawcutt, Daniel B. "Solving the problem of dose optimization of children's medicines." Expert review of clinical pharmacology vol. 11,3 (2018): 205-208. doi: https://doi.org/10.1080/17512433.2018.1431528
McWilliam SJ, Hawcutt DB. Solving the problem of dose optimization of children's medicines. Expert Rev Clin Pharmacol. 2018 Mar;11(3):205-208. doi: 10.1080/17512433.2018.1431528. Epub 2018 Jan 30. PMID: 29355041.
Copy Download .nbib Format: NLM
Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.

Rheumatology and therapy

Bluett J, Jani M, Symmons DPM.
PMID: 28808949
Rheumatol Ther. 2017 Dec;4(2):309-332. doi: 10.1007/s40744-017-0071-5. Epub 2017 Aug 14.

Lung disease is one of the most common causes of extra-articular morbidity and mortality in patients with rheumatoid arthritis (RA). Development of pulmonary manifestations may be due to the systemic disease itself; to serious respiratory adverse events such as...

Cite
Bluett J, Jani M, Symmons DPM. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. Rheumatol Ther. 2017;4(2):309-332doi: 10.1007/s40744-017-0071-5.
Bluett, J., Jani, M., & Symmons, D. P. M. (2017). Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. Rheumatology and therapy, 4(2), 309-332. https://doi.org/10.1007/s40744-017-0071-5
Bluett, James, et al. "Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis." Rheumatology and therapy vol. 4,2 (2017): 309-332. doi: https://doi.org/10.1007/s40744-017-0071-5
Bluett J, Jani M, Symmons DPM. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. Rheumatol Ther. 2017 Dec;4(2):309-332. doi: 10.1007/s40744-017-0071-5. Epub 2017 Aug 14. PMID: 28808949; PMCID: PMC5696283.
Copy Download .nbib Format: NLM
Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes.

RMD open

Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM.
PMID: 26848403
RMD Open. 2016 Jan 20;2(1):e000171. doi: 10.1136/rmdopen-2015-000171. eCollection 2016.

Treatment response to methotrexate (MTX) for rheumatoid arthritis (RA) is not universal and non-adherence may partially explain this. The aims of this systematic review were to: (1) summarise existing rates of adherence to MTX, (2) identify predictors of adherence...

Cite
Hope HF, Bluett J, Barton A, et al. Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open. 2016;2(1):e000171doi: 10.1136/rmdopen-2015-000171.
Hope, H. F., Bluett, J., Barton, A., Hyrich, K. L., Cordingley, L., & Verstappen, S. M. (2016). Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD open, 2(1), e000171. https://doi.org/10.1136/rmdopen-2015-000171
Hope, Holly F, et al. "Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes." RMD open vol. 2,1 (2016): e000171. doi: https://doi.org/10.1136/rmdopen-2015-000171
Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM. Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open. 2016 Jan 20;2(1):e000171. doi: 10.1136/rmdopen-2015-000171. eCollection 2016. PMID: 26848403; PMCID: PMC4731843.
Copy Download .nbib Format: NLM
Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

RMD open

Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, Lunt M, Watson K, Symmons DP, Hyrich KL.
PMID: 28123776
RMD Open. 2017 Jan 17;3(1):e000314. doi: 10.1136/rmdopen-2016-000314. eCollection 2017.

OBJECTIVE: To compare the risk of lupus-like events (LLEs) and vasculitis-like events (VLEs) in tumour necrosis factor-α inhibitor (TNFi)-treated patients with rheumatoid arthritis (RA) to those receiving non-biological disease-modifying antirheumatic drugs (nbDMARDs).METHODS: Patients were recruited to the British Society...

Cite
Jani M, Dixon WG, Kersley-Fleet L, et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open. 2017;3(1):e000314doi: 10.1136/rmdopen-2016-000314.
Jani, M., Dixon, W. G., Kersley-Fleet, L., Bruce, I. N., Chinoy, H., Barton, A., Lunt, M., Watson, K., Symmons, D. P., & Hyrich, K. L. (2017). Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD open, 3(1), e000314. https://doi.org/10.1136/rmdopen-2016-000314
Jani, Meghna, et al. "Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA." RMD open vol. 3,1 (2017): e000314. doi: https://doi.org/10.1136/rmdopen-2016-000314
Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, Lunt M, Watson K, Symmons DP, Hyrich KL. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open. 2017 Jan 17;3(1):e000314. doi: 10.1136/rmdopen-2016-000314. eCollection 2017. PMID: 28123776; PMCID: PMC5255894.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries